Sporadic Parkinson's disease may involve impaired mitochondrial quality control, and NAD augmentation or other mitophagy-promoting strategies could protect dopaminergic neurons. The key requirement is direct proof of mitophagy flux in vulnerable human dopaminergic neurons and disease-relevant alpha-synuclein models.
Heterozygous GBA1 loss of function reduces beta-glucocerebrosidase activity, disrupts lysosomal lipid handling, and promotes alpha-synuclein accumulation through a feed-forward lysosomal stress loop. The most actionable therapeutic strategy is GCase restoration or substrate correction in genotype-enriched GBA1-PD rather than broad TFEB activation alone.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
LysosomalUnspecified Mechanismneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
3/11
dimensions won
Mitophagy and NAD pathway enhancement in
9/11
dimensions won
GBA1/GCase restoration to reduce alpha-s
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.74
0.86
Evidence
0.66
0.86
Novelty
0.50
0.48
Feasibility
0.76
0.82
Impact
0.68
0.84
Druggability
0.78
0.86
Safety
0.70
0.68
Competition
0.56
0.58
Data
0.68
0.86
Reproducible
0.62
0.78
KG Connect
0.50
0.50
Score Breakdown
Dimension
Mitophagy and NAD pathway enha
GBA1/GCase restoration to redu
Mechanistic
0.740
0.860
Evidence
0.660
0.860
Novelty
0.500
0.480
Feasibility
0.760
0.820
Impact
0.680
0.840
Druggability
0.780
0.860
Safety
0.700
0.680
Competition
0.560
0.580
Data
0.680
0.860
Reproducible
0.620
0.780
KG Connect
0.500
0.500
Evidence
Mitophagy and NAD pathway enhancement in sporadic Parkinson'
No evidence citations yet
GBA1/GCase restoration to reduce alpha-synuclein pathology i
No evidence citations yet
Debate Excerpts
Mitophagy and NAD pathway enhancement in sporadic
4 rounds · quality: 0.76
Persona-Theorist
# Therapeutic Hypotheses in Neurodegeneration
---
## Hypothesis 1: TDP-43 Liquid-Liquid Phase Separation Dysregulation as a Central Mechanism in ALS/FTD
**Mechanism:** TDP-43 undergoes pathological...
Persona-Skeptic
I treat “confidence” here as confidence in the **therapeutic causal hypothesis**, not merely confidence that the pathway is biologically involved.
## 1. TDP-43 LLPS Dysregulation in ALS/FTD
**Weak l...
Persona-Domain Expert
As of April 29, 2026, I would triage these as **2 near-term translational programs**, **3 conditional/retool programs**, and **2 not-ready programs**.
| Rank | Hypothesis | Feasibility | Development ...
Persona-Synthesizer
{"ranked_hypotheses":[{"title":"GBA1/GCase restoration to reduce alpha-synuclein pathology in Parkinson's disease","description":"Heterozygous GBA1 loss of function reduces beta-glucocerebrosidase act...
GBA1/GCase restoration to reduce alpha-synuclein p
4 rounds · quality: 0.76
Persona-Theorist
# Therapeutic Hypotheses in Neurodegeneration
---
## Hypothesis 1: TDP-43 Liquid-Liquid Phase Separation Dysregulation as a Central Mechanism in ALS/FTD
**Mechanism:** TDP-43 undergoes pathological...
Persona-Skeptic
I treat “confidence” here as confidence in the **therapeutic causal hypothesis**, not merely confidence that the pathway is biologically involved.
## 1. TDP-43 LLPS Dysregulation in ALS/FTD
**Weak l...
Persona-Domain Expert
As of April 29, 2026, I would triage these as **2 near-term translational programs**, **3 conditional/retool programs**, and **2 not-ready programs**.
| Rank | Hypothesis | Feasibility | Development ...
Persona-Synthesizer
{"ranked_hypotheses":[{"title":"GBA1/GCase restoration to reduce alpha-synuclein pathology in Parkinson's disease","description":"Heterozygous GBA1 loss of function reduces beta-glucocerebrosidase act...